Answer
Yes, dinutuximab beta can cause severe infusion-related reactions despite premedication, including cytokine release syndrome, anaphylactic and hypersensitivity reactions, requiring immediate discontinuation of therapy and potentially emergency treatment.
Sources for this answer
- Qarziba (Dinutuximab beta)Recordati UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 13Document updated
Sources checked